TW200539898A - A method and device - Google Patents

Abstract

The invention relates to a method and device for treating or preventing or suppressing a disease or condition in a non-human animal. The method comprises the steps of providing a single delivery device containing two components for sequential delivery from the delivery device. A first component is delivered from the single delivery device into a teat canal of a non-human animal and subsequently the second component is delivered from the single delivery device into the teat canal. The components are delivered without substantial mixing of the components.

Description

200539898 IX. Description of the invention: [Technical field to which the invention belongs] The present invention relates to a method and device for administering two components into a nipple tube of a non-human animal. [Previous technology] Bovine mastitis is a serious, potentially fatal, inflammatory breast disease that is caused by a variety of infectious organisms, but is mainly caused by a variety of leathers of Staphylococcus and Streptococcus Caused by gram-positive bacteria and gram-negative bacteria Escherichia coli. The infection usually invades the breast through the nipple or striped tube. Mastitis is treated by infusion of various antibiotic waxes into the breast through the nipple or striped tube. In severe cases, high-dose antibiotics can also be administered by injection. A high proportion of mastitis occurs during the "dry" period before childbirth. The infection can then become clinically apparent during the dry phase or when lactation has resumed after childbirth. I have understood the treatment of mastitis with a pair of syringe packages, one of which contains-an antibacterial prescription and a second syringe containing a sealant or a barrier prescription. (1) The antibacterial prescription is delivered to the nipple tube first, and then the sealant prescription is used to form a physical barrier in the nipple tube to prevent the bacteria from entering the breast. These dual syringe packages are sold under the trade name Teat Seal ™. W094 / 13261 and WO95 / 31180 explain these dual syringes in detail and are incorporated herein by reference. Although the dual syringe system can provide an effective way to reduce the incidence of clinical mastitis, the use of these syringes may be time consuming, double the risk of introducing external environmental bacteria and increase the risk of causing striped tube epithelial damage by 99323. doc 200539898 additional non-reduction. The use of two syringes also throws up% force, increasing treatment costs and forming decomposable waste. The * Industry Needs-An improved method and device for preventing disorders in the breast that should at least overcome problems such as sheep. [Summary of the Invention] The present invention provides a method for treating pain, treating or preventing or inhibiting a non-human condition, including the following steps: disease or providing a single delivery device, f ^, two for sequential self The component delivered by the delivery device; Cardiac 1 delivered from the single delivery device into a first tube; and, 77, a nipple of a non-human animal, and then the second component was delivered from the single delivery device without Substantial mixing. In one embodiment, the delivery device includes a two-component injection injection device. The far-away component is separated by a barrier: the component enters the nipple tube and the septum and the The method includes the steps of delivering the first component from the injection device, at least partially releasing the barrier; and then delivering the second component from the syringe device. Λ & Example 4 Disease or condition is mastitis J_ The method of the present invention is used to treat or prevent microorganisms that cause mastitis. In another example, the osmium-brother component comprises a sealant. According to another aspect, the present invention provides a method for treating, preventing, or inhibiting mastitis or a microorganism that causes mastitis. The method includes sequentially delivering a single delivery device from 99323.doc 200539898. The steps of the prescription of organic medicine and a sealant to the nipple of a non-human animal are within 30 minutes. The name of the antimicrobial preparation and the sealant is $ 4 4 The head tube was not substantially mixed before. In an embodiment, the sealant formulation contains-a non-toxic heavy metal salt. In another embodiment, the sealant formulation contains 40% by weight of the heavy metal salt. In another embodiment, the sealed formulation comprises the heavy metal salt between 50% and 75% by weight. In one embodiment, the sealed prescription contains about 65% by weight of the heavy metal salt. In another embodiment, the heavy metal is bismuth. In another embodiment, the salt is a basic nitrate. In another embodiment, the sealed formulation includes a gel matrix. In another embodiment, the gel matrix is a gel based on aluminum stearate. In another embodiment, the gel matrix comprises liquid paraffin as a vehicle. In the usual examples, the component contains an antimicrobial preparation. In another embodiment, the antimicrobial agent is selected from any one or more of / 5-lactam antibiotics, polymyxins, glycopeptides (antibiotics), aminoglycosides (antibiotics), linco (醯) Amines (antibiotics), macrolides (antibiotics), pleuromutilin, "chloramphenicols" (antibiotics) such as chloramphenicol and flufenicol, tetracycline, sulfa drugs and powerful sulfa drugs such as Trimethoxyammonium ammonia% mixture with one or more amines, quinolone (antibiotic 99323.doc 200539898) and fluorinated quinolinone (antibiotic), cationic coccidiosis, coumarin: : For example, norbomycin, natural or synthetic peptides, aminoglycosides, antimicrobial peptides or antimicrobial preparations, lantibiotics, or other products against bacteria and other microorganisms. 〃 In another embodiment, the yS _ lactam is selected from any one or more of the main M, modified penicillin such as oxacillin, amoxicillin, & dolin, cephalosporin or Stone-lactamase inhibitors such as clavulanic acid-enhanced yS-lactam antibiotics. Say

^ The genus of moths and ticks is selected from any one or more of streptomycin, dihydrostreptomycin, neomycin, gentamicin, neomycin, kanamycin or kanamycin. In another embodiment, the antimicrobial preparation is selected from any one or more of macrocyclic vinegars (antibiotics), lincos (amidine) amines (antibiotics) or truncated: aurin, erythromycin, spirulina Leptin, Tylosin, Spirulinin, Inmicoxin, Lincomycin, Spectinomycin. Biliomycin or Thimlin. In another embodiment, the antimicrobial preparation is selected from any one or more of a mixture of potent amine drugs, trimethoxypyridine · ding plus complex amine · ding, amine dimethyl tidine, amine ortho Dimethoxine, diamine, dimethoxide, other diamine drugs, tertamine, minocycline or desoxycycline, gastrin) H-floxacin, ciprofloxacin, norfloxacin, teflon Shastar, difloxacin, or mapofloxacin. In one case, the first component contains an anti-inflammatory agent. In another embodiment, the anti-inflammatory agent is selected from any one or more of a steroid such as prednisolone, betamethasone, dexamethasone, butetaxel, or non-99323.doc 200539898 steroid such as gasnixin, County Buxaloxicam, Tiposarin, Yier # Acid | fen, Vindaprofen, Mei

: This: In another aspect, provided, the J a = Γ head tube-device, the set includes: a tube for receiving a first component, an outlet nozzle at one end of the tube, a An internal container for containing a second component, a barrier for separating the -th-component and -the second component, and a delivery member for passing the The cartridge delivers a first component and then a second component from the internal container. In one embodiment, the barrier is normally closed. In another embodiment, the barrier is releasable to deliver the second component. In another implementation, the barrier is defined by at least a portion of the internal device. In one embodiment, the barrier comprises one or more channels. In another embodiment, when the barrier is released, the one or more channels are opened to deliver the second component through the one or more channels. In another embodiment, the device includes an exciter for releasing the barrier. In one embodiment, the exciter includes a mechanical exciter member. In another embodiment ' The trigger comprises at least one protruding member. In another embodiment, the exciter is located in the barrel. In one embodiment, the exciter is located adjacent to the outlet nozzle. In another embodiment, the exciter includes one or more channels. 99323.doc -10- 200539898 In another embodiment, the exciter injury is not known. Mouth 1 糸 is configured to engage with the internal container 'to provide a direct channel to the spleen _ 4 / V 1, first, and wound from the internal container to the outlet nozzle. In an embodiment, the delivery member includes a pusher for the cartridge. In another embodiment, the barrier is released by the delivery member. In another embodiment, the inner container includes an inner cylinder which is located in an outer cylinder defined by the syringe cylinder. In one embodiment, the inner cylinder is tightly fitted in the outer cylinder. In another embodiment, the delivery member includes the inner barrel. In another embodiment, the inner cylinder defines a push rod for the outer cylinder. In an embodiment, the delivery member comprises-for the pusher. In another embodiment, the inner cylinder contains an engaging member for engaging with the outer cylinder during assembly. In another embodiment, the engagement member includes an external seal. In the-embodiment, the outer cylinder contains a joining member for engaging with the inner cylinder. In another embodiment, the outer cylinder includes a locking ring for engaging the inner cylinder. In another embodiment, the inner cylinder includes an engaging member for engaging with the push rod. In an embodiment, the inner cylinder contains a locking ring for engaging the push rod. In another embodiment, the container comprises a bag. In another embodiment, the container contains a roll. 99323.doc -11-200539898 In an embodiment, the container is part of an attached delivery member. Onto the delivery member or forming the ruptured member of the barrier in another embodiment. The exciter includes a mechanism for at least partially releasing the thorium rupture member and includes a mechanical rupture component. The rupture member includes at least one blade. "The rupture component contains at least one tooth.

In another embodiment, in one embodiment, in another embodiment, in another embodiment, in another embodiment, in another embodiment, in another embodiment, the 0,5 Hai fracture component is located at Inside the tube. The breaking member is located adjacent to the outlet nozzle. The tube contains a first component. In a preferred embodiment, the inner Qiujiao Liukou Puguguner contains a second component. In another example, the first group is known to contain a sealant prescription. In another embodiment, a set of wounds is delivered from the cartridge and a second wound is delivered with the internal container, and the components are not substantially mixed. In the example, the '4 sealant prescription may include the above-mentioned sealant prescription.

In another example, the antimicrobial formulation is a biological formulation. Upward anti-U [Embodiment] The present invention provides an injection crying at the time of △ t, which allows two immiscible portions (such as an anti-microbial nan f, 、, 剡 剡 剡 prescription and a seal Prescribing) is delivered sequentially to the nipple meat of non-human animals. # — U i The bifurcation prescription and antimicrobial preparation are separately contained in a single, + early injection device. This allows the product to be stored without affecting the stability of either component at 99323.doc -12-200539898. The Pei Chi can also deliver the prescription of the antimicrobial preparation first, and then the sealant. The sealant prescription effectively forms a physical barrier in the nipple tube that prevents any further penetration into the nipple tube. The sealant prescription also prevents the antimicrobial formulation phase from leaking out or being squeezed out of the nipple due to gravity or hydrostatic force. The sealed formulation may contain a viscous oil-based wax containing a high proportion of heavy metal salt, basic bismuth nitrate. The product is based on Seal ((> Qss

The brand name of Vetpharm Group) is detailed in ~ 98/26759 and contains a non-toxic heavy metal salt in a gel matrix. The matrix is a gel based on aluminum stearate. The gel preferably contains a vehicle, such as liquid paraffin. = The gel can also contain a polyethylene gel. The gel can be based on low density polyethylene or rhenium density polyethylene. Preferably, the content of the heavy metal salt is higher than 40% by weight, preferably between 50% by weight. /. And 75% by weight, preferably about 65% by weight. The sealed prescription prevents the infection from entering the breast through the nipple or the striped tube by virtue of its combination of viscosity, density and adhesion. The antimicrobial or anti-inflammatory prescription may be selected from any one or more of various organisms (especially including Gram-positive and Gram-negative bacteria, yeast, fungi) known to be effective in treating, preventing and eliminating mastitis and mastitis. And rickettsia). The antimicrobial or anti-inflammatory material may include, inter alia, lactam antibiotics such as penicillin and cephalosporins, and yS lactam antibiotics enhanced by lactam inhibitors such as clavulanic acid, polymyxins, glycopeptides (Antibiotics), aminoglycosides (antibiotics), linco (s) amines, macrolides 99323.doc -13- 200539898 (antibiotics), pleuromutilin, "chloramphenicols" such as chloramphenicol And flufenicol, tetracycline, sulfa drugs and powerful sulfa drugs such as a mixture of trioxo diaminopyrimidine and one or more continuum drugs, quinolones (antibiotics) and fluorinated quinolins. Antibiotics), cationic coccidiosis drugs, coumarins such as norbomycin, natural or synthetic peptides, lantibiotics, and other antimicrobial products against bacteria and other microorganisms. Other antimicrobial preparations may be selected from any one or more of the macrolides (antibiotics), linco (s) amines (antibiotics) or pleuromutilin, erythromycin, spirulina, tylosin, spirulina Leptin, Telmicoxin, Lincomycin, Spectinomycin, Pirithromycin, Thimulin, Powerful Sulfa Drug Mixtures, Diaminopyrimidine plus Sulfamethoxine, Sulfamethazine, Sulfamethoxine Dioxopyrimidine, diamine dimethoxide or other diamines, oxytetracycline, minocycline, or deoxytetracycline, quinolinium fluoride, enflufloxacin, ciprofloxacin, nordox Ofloxacin, dalfloxacin, difloxacin, or maboxacin. The second component is selected from any one or more of an anti-inflammatory compound, a steroid such as prednisolone, betamethasone, dexamethasone, butaxone, or a non-steroid such as nisin, ketoprofen, Carprofen, vidalofen, meloxicam, teposarin, irinotelic acid, nimesulide, or tofenamic acid. // Other biological agents < anti-inflammatory compounds can also be used in the treatment of breast infections in non-human animals. Used 杬 ^. These antimicrobial preparations or anti-inflammatory materials can be formulated alone or in combination with liquid peptides, waxes, solutions, suspensions, and compounds in water, oil (animal oil, vegetable :: oil from other sources), or other organic media. Agent. Examples of other formulations can also be used 99323.doc -14- 200539898 such as solubilizers, suspending or emulsifying agents, viscosity modifiers, surfactants, encapsulants, and other agents that regulate the release rate of the compound (s) from the formulation Components, formulas, tinctures, and hydration agents that maintain intermediate values of prescriptions, anti-inflammatory agents such as a variety of steroidal and non-steroidal compounds used for this purpose, and a variety of preservatives commonly used in pharmaceutical preparations. Consider the attached drawings 1 to 8. These drawings illustrate, "" bucket ... η π "

1 The 'main shooter device 1' in this example includes an inner tube 2 and an outer tube 3. The outer cylinder 3 has a nozzle 4. The inner cylinder 2 contains a group of wounds containing a sealant 9. The sleeve 2 has a barrier or septum 5 at its distal end. A push rod 6 is inserted above the proximal sealant 9 of the inner cylinder 2. An antimicrobial agent or anti-inflammatory agent component 10 is contained in the outer cylinder 3 below the inner cylinder 2. In use 2, insert the nozzle 4 into a nipple tube of a non-human animal such as a cow. 2 The inner cylinder 2 is pushed through the outer cylinder 3 by the pusher 6 to discharge the antimicrobial agent = the inflammatory agent component is called Fig. 8 (a). After the antimicrobial preparation or anti-inflammatory component 10 has been discharged (pictured), further push down on the inner cylinder 2: dry 6 to discharge the sealant 9 in the inner cylinder 2. The pressure of the push rod 6 can be enough to make the inner cylinder shoot up: the wall 'septum 5 releases or ruptures, so that the sealant 9 is discharged from the injection device through the nozzle 4 and enters the nipple tube. (I The rupture member is located in the outer cylinder The diaphragm adjacent to the outlet in 3 increases or decreases or ruptures or opens. It can be used to make the barrier / / = Γ, and two its illustrations. Another-similar to the syringe of Figures 1 to 8 ^ :; people and similar parts are designated the same The reference number. The injection tube W inner tube 2 and-outer tube 3. The outer tube 3 has-nozzles. In the example, the barrier is defined by a number of needle tips protruding upwards of different lengths 99323.doc 200539898 50. The exciter is released. The diaphragm / barrier has a portion η, the portion 51 is pierced by the needle tips 50 to allow the sealant component to be discharged. The distal end of the inner tube 2 has a seal sealed to the inner side wall of the outer tube 3 Pieces or frills... Qian Figures 1G to 13, which illustrate another syringe that is still similar to the syringe of Figure., And similar parts are assigned the same reference number .: The syringe device 1 contains an inner cylinder 2 And an outer cylinder 3. The outer cylinder 3 has a nozzle 4. In this example, the barrier bag A valve 60 located at the distal end of the inner cylinder 2. The trigger 61 protrudes upward from the lower wall of the outer cylinder. In use, when the inner cylinder 2 is in the configuration of Fig. 11, the valve is engaged by The activator 61 is lifted and the sealant component 9 in the inner cylinder 2 passes through the syringe nozzle *. When the push rod 6 is pushed down, the 'inner cylinder 2 also goes down through the outer cylinder 3. 2: The outer side is in the outer cylinder 3 The inner tube 2 fits tightly, so that the inner tube 2 itself serves as a delivery device or pusher to deliver the first component from the outer tube 3 through the nozzle 4. See Figures 14 to 16 for another illustration of The injection syringe in Figure α 13 is similar to the syringe and the similar parts are assigned the same reference number. The injector device includes an inner cylinder 2 and an outer cylinder 3. The outer cylinder 3 has a nozzle 4. The inner cylinder 2 contains-sealed Agent component 9. A pusher 6 is inserted above the proximal sealant component 9 of the inner cylinder 2. The antimicrobial agent 10 is contained in the outer cylinder 3. When in use, the nozzle 4 is inserted into the nipple tube 2.内。 The inner tube 2 includes an outlet 75 located in the distance 74 and the barrier ribs include a valve 70 accommodated in the outlet 75. The valve 70 is the same as the outside 3 During the delivery of the first component, it is usually closed (14⑷, 一). An exciter 71 protrudes upward from the lower wall of the outer tube 3. In use, all of the first-new portions have been delivered and the inner tube 2 The valve 70 can be released by engaging the trigger 7 in the figure i4 (c), so that the sealant component 9 in the inner cylinder 2 99323.doc -16-200539898 can be used for the next day. ~ Into the syringe nozzle 4, the side channel 76 inside the valve passes through the outlet-the inlet end is formed to engage with the push rod 6 and contains-located near it Γ ::: Γ: retaining ring 173. the inner tube 2 contains-the distal part m and a near W knife 179, the distal portion 178 has-the inner diameter of the proximal portion 179 is smaller than the inner #. The push rod 6 includes a seal 77, the cylinder's locking ring 173. Thus, the push rod 6 is in a sealed manner with: The inner cylinder 2 further includes an outer seal 72 for engaging the inner cylinder of the outer cylinder 3. The outer seal 72 may, for example, comprise an integrally formed seal or an O-ring embedded in a recess 172 of the outer side wall of the inner cylinder 2. The outer seal 72 is located near the distal end 74 of the inner cylinder. The inner wall of the outer cylinder 3 is formed for engagement with the inner cylinder 2 and includes a locking ring 73 located between the proximal end and the distal end thereof for engaging the outer seal 72 of the inner cylinder 2. The outer tube 3 includes a distal portion 78 and a proximal portion. The distal portion 78 has a smaller inner diameter than the inner diameter of the proximal portion 79. The outer seal 72 passes over the lock ring 73 of the outer cylinder 3 and is engaged with the outer cylinder in a sealed manner during assembly. In this way, the prescription of the antimicrobial preparation or the anti-inflammatory agent can be prevented from entering between the two cylinders when the pusher 6 is pressed. The valve 70 includes a plurality of grooves or openings that can be exposed when the valve 74 is released to allow the sealant component to flow out through the valve. So, — release the valve, these define the channel of the sealant component channel 76 * J open 0 The valve is shown in Figure 14 (c), the outlet 75 and valve 70 engage the trigger 71 99323.doc 17.200539898 70 was released, thereby opening the channel 76 into the exciter 71. The exciter has a shape corresponding to the shape of the outlet, so that a part of the exciter can be included in a part of the outlet 75. The valve channel 76 is in common with the activator 70. A closed channel is defined for the direct delivery of the sealant component from the inner barrel into the syringe nozzle. In use, the anti-microbial preparation is discharged by pushing the inner cylinder 2 through the outer cylinder 3 by the push rod 6 (Fig. ^ ...)). The inner cylinder 2 has a geometric shape of the pusher 6 on the outer side, so that the inner cylinder 2 itself can be used as a pusher. After the antimicrobial preparation 10 is discharged (Fig. 14 (b)), the pusher 6 on the inner cylinder 2 is further depressed to discharge the sealant 9 from the inner cylinder 2. The valve 70 is released by engaging the trigger 71 on the inner cylinder, and the sealant component 9 in the inner cylinder 2 is allowed to pass through these valve channels into the injection nozzle 4 and be discharged into the nipple tube (FIG. 14 ( c)). One of the advantages of the valve-shaped barrier in this embodiment is that no part of the barrier is in danger of moving. The barrier is held together with the syringe. Referring to Figures 17 to 18, a syringe device 81 (which is similar to the syringe of Figures 1 to 16 and similar parts are assigned the same reference numbers) is illustrated for an alternative embodiment of the present invention. The syringe device 81 includes a barrel 3, an outlet 4, and a push rod 6. The two incompatible components 9 and 10 are placed in the barrel 3 of the syringe device 81. The two components such as an antimicrobial agent and a sealant 9 are separated from each other by a barrier / diaphragm. The antimicrobial preparation ⑺ is placed in the cartridge 3, and a sealant 9 is placed in a container "for example, a bag defined by a septum 87 providing a barrier outer side. The container 86 may contain a pouch, the sealant system It is filled into the capsule during production. Then, the capsule can be easily dropped into the syringe barrel 3 before the push rod 6 is inserted. 99323.doc -18- 200539898 Η: The nozzle 4 of the device 81 is inserted into a nipple tube 16 At this time, the user pushes the pusher 6 to deliver the antimicrobial preparation 10 from the syringe device to the nipple tube (Fig. 17。). After the antimicrobial preparation 10 is discharged from the syringe device, will further force be applied to the pusher to puncture or Break the volume, and let the sealant 9 flow out and be delivered into the nipple tube (Figure j 7 (b)). V)} Figure 17 (d) shows that the non-sealed prescription 9 and the antimicrobial formulation 10 are at the delivery position. When it comes to the nipple of a non-human animal, the injection device may include a rupture member, such as a w 88 'located at the distal end of the barrel 3, to help puncture or break the container 86. It should be understood that, for ease of manufacture and use, 6. In this case, the P is all first on all Γ rods Do n’t make contact with the rupture device until it has been substantially discharged from the device. When delivering a sealant 9 and an anti-agent or anti-inflammatory liniment to a non-human animal nipple tube, a virtual prescription 丨 * ** is shot below the biological nipple The device is usually positioned vertically at the I :: side with the delivery nozzle at the top. Sealant Formulation 9 has a specific gravity of a distant microbiological preparation or anti-inflammatory agent prescription Η), and therefore during the formulation or anti-inflammatory agent prescription In this package, the household prescription is still at the lower end of the containing antimicrobial agent or anti-inflammatory rate # 方 之 管 3. In this case, the content of the biologic or anti-inflammatory drug is strict. Although all anti-micros were in contact with the rupture device, the MG was delivered into the nipple with reference to Figs. 19 and 20, which illustrates another 90 of the present invention. The syringe is equipped with an incident beam. The clothes set 4 and 90 includes an inner tube 92 and an outer tube 93. The outer tube 93 is 99323.doc -19- 200539898 and has a nozzle 94. The inner tube 92 includes a rupturable / breakable barrier or diaphragm at its distal end. And a putter 98 at its proximal end. The antimicrobial preparation is kept outside 93. In use, insert the nozzle 94 into a nipple tube 16. Push the inner tube 92 through the outer tube 93 to discharge the antimicrobial preparation (Figure 20 (b)). The flange 97 and a flange 99 surrounding the proximal end of the outer tube 93 become easy. After the antimicrobial preparation 10 has been discharged (Fig. 20 (c)), 'press the pusher 98 on the inner tube 92 to The inner cylinder 91 discharges the sealant 9. The pressure of the push rod 98 is sufficient to cause the barrier / diaphragm 96 on the inner cylinder 92 to be broken or ruptured, so that the sealant 9 is discharged from the syringe device through the nozzle 94 and enters the nipple tube (Figure 20 ( c)). Alternatively, a rupture member, such as a sharp tooth located in the opening of the snoring hole in the outer cylinder 93, may rupture the barrier / diaphragm 96. A seal 96 may be provided at the front end of the Nei 92 at Zhuang She to provide a positive pressure seal. The inner syringe can be molded with an insecure, breakable barrier / diaphragm 95 over the exit opening. It should be understood that the sealant portion of the prescription can be made in a device and then combined with the antibacterial portion of the prescription in the same or a different device at a later stage. This description is not limited to the embodiments described above, and these embodiments may vary in details. [Brief description of the drawings] The present invention will be more clearly understood by reading the detailed description of the present invention given by way of example only with reference to the drawings. FIG. 1 is a schematic cross-sectional view of a syringe device according to the present invention. Fig. 2 is a sectional view of an inner cylinder of the device; 99323.doc -20- 200539898 Fig. 3 is a sectional view of an inner barrel of Fig. 2 with a sealant component in place. Fig. 4 is an inserted rod Figure 3 is a cross-sectional view of the inner tube; Figure 5 is a cross-sectional view of an outer tube of the device; Figure 6 is a drawing of an antimicrobial component in an appropriate position; w I sectional view 7 is an assembled Sectional view of the syringe device; Figures 8 (a) to 8 (c) are sectional views of the syringe device in use;

Fig. 9 is a sectional view of another syringe of the present invention; Fig. 9 (a) is an enlarged view of a part of the syringe of Fig. 9; Figs. 10 to 12 are sectional views of another syringe of the present invention in different use configurations; Fig. 13 is a top plan view of the device of Fig. 9; Figs. 14 (a) to 4 (c) are the present hair slaves in different configuration states; a sectional view of the main shooting device; °° Fig. 15 is a view An exploded view of the components of the 14 syringe; Figure 16 (a) is a detailed diagram of a part of the syringe of Figure 14 and Figures 16 (b) and 16 (c) are respectively shown in Figures 14 (13) and (c) A detailed perspective view of one of the devices of the configuration; ^ FIG. 17 is a view of a syringe device port in another embodiment of the present invention, and FIG. 18 (a) to 18 (d) are views in use Sectional view of device 17 Figure 19 is a schematic cross-sectional view of another injection device of the present invention; and Figures 20 (a) to 20 (c) are cross-sectional views using the syringe device of Figure 19 in Figure 0 99323.doc • 21-200539898

[Symbol description of main components] 1 Injector device 2 Inner tube 3 Outer tube 4 Nozzle 5 Baffle / diaphragm 6 Push rod 9 Sealant component 10 Antimicrobial preparation 16 Nipple tube 20 Nipple tube 30 Tooth 50 Needlepoint 51 Part 53 Seal or pleated Side 60 valve 61 trigger 70 valve 71 trigger 72 outer seal 73 lock ring 74 distal end of inner barrel 75 exit 76 channel 99323.doc -22 200539898

77 78 79 81 86 87 88 90 92 93 94 95 96 97 98 99 172 173 178 179 Seal distal part proximal part syringe device container outer diaphragm sharp tooth syringe device inner cylinder outer cylinder nozzle barrier / diaphragm barrier / diaphragm (seal Pieces) Flange putter Flange Outer wall recessed locking ring distal part proximal part 99323.doc -23-

Claims (1)

200539898 Scope of patent application: A method of treating or preventing or inhibiting non-human beings of animal-like diseases or conditions. The method includes steps. The device includes two methods for sequentially delivering a single delivery device from the delivery device to the delivery device. A single component is delivered from the single delivery device to the head tube; the milk of a non-human animal is subsequently delivered from the single delivery device to the second component into the nipple tube, and the special component is not substantial Sexual mix. 2: The method of the request item 'wherein the delivery device includes a syringe device comprising two groups of = the components are separated by a barrier and the method includes the following steps: delivering the first from the injection device Component; at least partially release the barrier; and then deliver the second component from the injection device. 3. A method as claimed, wherein the disease or condition is mastitis. 4. If requested, the method of item 2 is used to treat or prevent a microorganism that causes mastitis. 5. A method as claimed in any of item 4 in which the second component comprises a sealant. 6. A method for treating, preventing or inhibiting mastitis or mastitis-causing microorganisms' The method includes the following steps: sequential delivery from a single delivery device-prescription of an antimicrobial preparation and a sealant to a nipple of a non-human animal In the tube, the prescription of the antimicrobial agent and the sealant were delivered into the nipple tube & ~ at 99323.doc 200539898. Month]! Consistent blending is delivered to the nipple tube 7. · As requested in method 5 or 6, ... metal salt. Eight " Hai Shifeng's prescription contains a non-toxic heavy 8. The method of claim 7, a heavy metal salt. ° Hai sealant prescription contains more than 40 weight 0 / 〇y. Gekou w only 8 square centimeters, the amount of Gan Gan% to 75 weight eight hundred and five Hai Ye, sealant prescription contains heavy metals between 50 li / 0 salt. 10. If any of the items 7 to 9 is about 65 weight ❶ /. Of heavy metal salts. The sealant prescription contains 11. As claimed in any one of claims 7 to 10. 12. As described in any of claims 7 to 10: two ': The heavy metal is Syria. salt. A method, wherein the salt is basic nitric acid 13. The gel-containing matrix according to any one of claims 5 to 12. The method, the method, and the sealant prescription kit 14. The gel of the method of claim 13. The material base is based on stearic acid inscription 15. As stated in item 13 or 14 of the claim, the medium gel base contains liquid paraffin as a vehicle. % 16. If requested, go to 5 or 7 to 15 and go to step 8a, where the first set of wounds contains an antimicrobial preparation. 17. The method according to claim 6 or 16, wherein the antimicrobial agent is selected from any one or more of a lactam antibiotic, polymyxin, glycoside (antibiotic), aminoglycoside (antibiotic), linco (醯) Amines (antibiotic responsibility), big 99323.doc 200539898 private vinegars (antibiotics), pleuromutilin, "chloramphenicols" (antibiotics) such as lactoferrin and flufenicol, tetracycline, continuation amines Medicines and potent flavin amines such as dimethyl _ jin + A _ one lice cyanazine and one or more sulfonamides are mixed Antibiotics), cationic, insecticides, coumarins such as norbomycin, natural or synthetic vicissitudes: earth glycosides (biotins), antimicrobial peptides or antimicrobial agents, flat wool sulfur antibiotics, or Other products resistant to bacteria and other microorganisms. 2. The method according to item 17, wherein the lactam is selected from any one or more of cyclamycin, modified penicillin such as coxcillin, amoxicillin, ampicillin, cephalosporin, or by ^ endo Aminase inhibitors such as clavulanate enhanced / 5-lactam antibiotics. The method of the evening moon officer 17 ', wherein the amino sugar buds are selected from the group consisting of U-, U-dihydrostreptomycin, neomycin, gentamicin B, apramycin or kanamycin.锨 素 2 ·· The method according to claim 6 or 16, where the antimicrobial preparation is selected from any of the macrocyclic _ (antibiotics), linco (brewed) amines (anti- or cut-off) Short-sided ear ear, erythromycin, spiramycin, tylosin, spiroxamine, telmicoxin, technical aa forest. Linkosin, spectinomycin, piromycin or thimium 21 · The method according to claim 6 or 16, wherein the antimicrobial agent is selected from the group consisting of: -He- = a strong rhyme drug mixture, trimethoxypyridine diamine: pyridine, sulfone r: ^, sulfamethazine, Sulfa o-dimethoxypyrimidine 3 female monomethoxypyridine. Diazine or other lutein drugs, termioxin, minocycline 99323.doc 200539898 voxel or deoxytetracycline, quinolinone (antibiotic), Enfloxacin, Proprofloxacin, Norfloxacin, Dalfloxacin, Difloxacin, or Marboxacin. 22. The method of any one of claims 1 to 5 to 7 to 15, wherein The first component comprises an anti-inflammatory agent. 23. The method of item 22, wherein the anti-inflammatory agent is selected from any one or more steroids such as prednisolone , Betamethasone, dexamethasone, butepine, or non-steroids such as Inisin, ketoprofen, carprofen, vildolofen, meloxicam, sarsalin, pantemic acid, nicotine Mesulide or tofenamic acid. 24. 25. Methods illustrated in these figures. Syringe in a non-human animal nipple tube A substantially as described above with reference to a device for delivering components to a device comprising : A cylinder for containing a first component, an outlet nozzle at one end of the cylinder, One is used to contain the inner volume of the second component, one is used to separate the first component plate_Chu Yi " " the barrier of the second component, and one is used to pass from the tube through the outlet nozzle哕 内邱 六 泪, choose ... 铉 & 苐 one set and then 26. The syringe device of claim 25, wherein. Hei h ② delivery: ^-brother two component delivery components. " The barrier is normally closed 27. If the syringe set of item 25 or 26 is requested, the system is closed. Send the second component. The early wall can be released for delivery, wherein the barrier is defined by at least a part of the inner 28. syringe device container as claimed in claims 25 to 27. 99323.doc 200539898 29. The syringe device of claim 25 to 28, wherein the barrier contains one or more channels. 30. The syringe device of claim 29, wherein the one or more channels are opened upon release of the barrier to deliver the second component through the one or more channels. 31. The syringe device of claims 25 to 30, wherein the device comprises an activator for releasing the barrier. 32. The syringe of claim 31, wherein the exciter comprises a mechanical exciter member. 33. The syringe of claim 31 or 32, wherein the trigger comprises at least one protruding part. 34. The syringe of any one of claims 31 to 33, wherein the trigger is located in the barrel. 35. The syringe of any of claims 31 to 34, wherein the activator is located adjacent to the outlet nozzle. 36. The syringe device of claim 31 to 35, wherein the trigger comprises one or more channels. 37. The syringe device of claim 31 to 36, wherein the trigger is configured to engage a side inner container to provide a direct passageway for delivering the second component from the inner container to the outlet nozzle. 38. The syringe of any one of claims 25 to 37, wherein the delivery member includes a pusher for the barrel. 39. The syringe device of any one of claims 25 to 38, wherein the barrier is released by the delivery member. 99323.doc 200539898 40. The syringe of any one of claims 25 to 39, wherein the content is located in an outer barrel defined by the barrel of the syringe ^ -41. As claimed in claim 4. The syringe, in which the inner cylinder is closely fitted to the cylinder. 42. If any of the claims 40 or 41-the note of the item includes the inner cylinder. ^ 〃 巾 _ 送 件 包 43. If you ask for attention + crying for items 40 to 42, the main shot is, where the inner tube defines a push of the tube. Pusher for the outer cylinder The delivery kit 44. The syringe as claimed in any one of claims 40 to 43, which includes a pusher for the inner cylinder. 45. A syringe as claimed in claims 40 to 44, wherein the engaging member engages the outer cylinder. 3 daggers 3 are used in assembly 46. Injector pieces as requested in item 45. The mouthpiece contains-an external seal 47. A joining member that engages with the inner cylinder as claimed in any of 45 or 46. .... The outer cylinder contains the syringe of 48. as claimed in claim 47, wherein the outer engaging locking ring. 3 Engagement member for use with the inner cylinder 49. A syringe as claimed in any one of claims 40 to 48 for engaging the pusher. ^ Zhong Jingjing included the syringe of 50. as in claim 49, wherein the insider engaged a locking ring. 11 3 One to use with the putter • If the note of any one of claims 25 to 39 contains a bag. Table setting 'wherein the container package 99323.doc 200539898 52. The injection cryo-sigma table setting according to any one of claims 25 to 39, wherein the container contains a capsule. 53. The injection of any one of Claims 51 or 52 ^ TQ Valley is attached to or forms an integral part of the delivery device. 54. The injection cryoprobe set of any one of claims 31 to 53, wherein the stimulator pack S is a ruptured member for at least partially releasing the barrier. 55. The syringe of claim 54 wherein the rupture member comprises a -mechanical rupture component. 56. The syringe of claim 55, wherein the ruptured component includes at least one blade. 5 7. The syringe of claim 55 or 56, wherein the ruptured part contains at least teeth. Wherein the ruptured part is 58. The syringe of any one of claims 55 to 57 is located in the barrel. The rupture part is ’wherein the tube contains a component containing a micro-antibody’ where the internal volume 59. The syringe of any one of claims 55 to 58, which is located adjacent to the outlet nozzle. 60. A syringe assembly as claimed in any one of claims 25 to 59-a first component. 61. The syringe device of claim 60, wherein the first biological agent is prescribed. 62. The syringe device of any one of claims 25 to 61 contains a second component. The medium-degree component contains a seal 63. The syringe device of claim 62, wherein the dose is prescribed. 99323.doc 200539898 64. The syringe device of any one of claims 25 to 63, wherein a first component is delivered from the cartridge and a second component is subsequently delivered from the internal container, and the groups Portions are not substantially mixed. 65. A syringe device substantially as explained above with reference to the drawings. 99323.doc